SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-020320
Filing Date
2024-04-17
Accepted
2024-04-17 16:23:40
Documents
14
Period of Report
2024-04-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20027138_8k.htm   iXBRL 8-K 30754
2 EXHIBIT 10.1 ef20027138_ex10-1.htm EX-10.1 154015
  Complete submission text file 0001140361-24-020320.txt   351353

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ocup-20240411.xsd EX-101.SCH 3865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20240411_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20240411_pre.xml EX-101.PRE 16044
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20027138_8k_htm.xml XML 4087
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 24851359
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)